Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for Pemazyre

Release date: 2024-07-10 14:51:29     Recommended: 93

07L0997_23 培米替尼 批文_00.jpg

PEMAZYRE is suitable for treating adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma, with fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangements detected through FDA approved testing. PEMAZYRE is suitable for treating adult recurrent or refractory bone marrow/lymphoid tumors (MLN) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.

Company News

Research News

Drug news